About Careers Internship MedBlog Contact us

High Rates of Liver Disease Progression Seen in Non-alcoholic Fatty Liver Disease Patients

by Colleen Fleiss on April 23, 2019 at 6:59 AM
Font : A-A+

High Rates of Liver Disease Progression Seen in Non-alcoholic Fatty Liver Disease Patients

Among patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) increased rates of liver disease progression and mortality are observed, revealed two independent national studies.

The studies reported today at The International Liver Congress™ 2019 in Vienna, Austria, found that within 10 years of diagnosis, up to 11% of patients with NAFLD/NASH had progressed to advanced liver diseases (defined as NAFLD/NASH patients with compensated cirrhosis [CC], decompensated cirrhosis [DCC], liver transplant [LT] or hepatocellular carcinoma [HCC]), and up to 27% of patients with NAFLD/NASH and CC had developed liver decompensation.


Fatty liver is a complex condition that affects up to one-quarter of adults worldwide. The condition is considered to be the liver manifestation of metabolic syndrome and encompasses a histological spectrum from the relatively benign non-alcoholic fatty liver to NASH, which typically has an aggressive course. NAFLD/NASH can lead to cirrhosis or HCC, and is set to become the predominant cause of liver disease in many parts of the world; however, their natural history remains incompletely defined.

In the first study, 215,655 NAFLD/NASH patients were identified retrospectively from a German insurance claims database (InGef; 2011-2016) with 100,644 new events of different liver severity stages identified during the follow-up: 79,245 events (78.7%) of non-progressive NAFLD/NASH, 411 events (0.4%) of CC, 20,614 events (20.5%) of DCC, 11 events (0.01%) of LT and 363 events (0.4%) of HCC. Amongst those with advanced liver diseases, mortality rate during 1 year of follow-up increased by up to 50% (range 8.8-51.2%), compared with non-progressive NAFLD/NASH patients (1.2%, p<0.0001). This trend continued over 5 years of follow-up, with only 2.8% of the non-progressive NAFLD/NASH patients dying, compared with 14.8% of CC patients, 25.6% of DCC patients, and 64.5% of HCC patients. After adjusting for patient demographics and comorbidities, the mortality risk increased significantly (p<.0001) with liver disease progression. As compared to non-progressors, the risk of mortality for NAFLD/NASH patients with CC, DCC, LT and HCC was 2.71, 4.21, 2.23 and 13.69 times higher respectively.

'Perhaps most worryingly, during the 5-year study period, 11% of the NAFLD/NASH patients progressed to advanced liver diseases and 17% of CC patients progressed to DCC, after accounting for any dying patients," said Professor Ali Canbay from the University of Magdeburg Medical School in Magdeburg, Germany, who presented the study findings. 'This demonstrates very clearly the need for early detection and effective treatment to prevent progression and potentially reduce mortality."

In the second study, French investigators identified 125,052 NAFLD/NASH patients from the French National Database on hospital care (PMSI; 2009-2015), of whom 1,491 (1.2%) were diagnosed with CC, 7,846 (6.3%) with DCC, and 1,144 (0.9%) with HCC. As was seen in Germany, a small cohort of patients progressed rapidly, with 5.6% of NAFLD/NASH patients progressing to more severe liver disease during 7 years of follow-up, and 27.5% of NAFLD/NASH patients with CC progressing to DCC. Mortality was high across all cohorts and increased with liver disease progression. After 1 year, 2.1% of NAFLD/NASH patients, 4.6% of CC patients, and 19.1% of DCC patients had died. The corresponding mortality rates after 7 years of follow-up were 7.9%, 16.3%, and 34.6% respectively.

'Before this study, we had very limited data on the disease progression and mortality of NAFLD/NASH patients in our country,' explained Professor Jerome Boursier from Angers University Hospital in Angers, France. 'We were surprised by the high overall mortality rate among these patients (7.9%) - almost twice that of the general population of a similar age - as well as the apparent rate of under-diagnosis of cirrhotic patients, the majority only being identified following a decompensation event.'

'This shows us we must direct greater effort into finding and treating NAFLD/NASH patients as early as possible, so we can stop or even reverse disease progression.'

Professor Philip Newsome (Vice-Secretary EASL) said, "These data demonstrate the significant morbidity and mortality found in patients with NAFLD and reinforces the need to identify those patients most at risk for appropriate treatment."

Source: Eurekalert


Recommended Readings

Latest Alcohol & Drug Abuse News

Adolescent Binge Drinking Can Cause Long-Term Brain Changes
If teenagers' binge drinking strikes neurons off, the brain cells may not be able to execute their function properly, even if the alcohol consumption stops.
 Quit Smoking Fast With Treatment Clearing Nicotine Metabolism Disparities
A new study analyses Whether treatment support can optimize nicotine replacement therapy to quit smoking faster, using biomarker nicotine metabolite ratio.
How Genetic Risk Information Can Help People Avoid Alcohol Addiction?
The genetic risk scores developed was found to be helpful in preventing and treating alcohol addiction.
New Jersey Medicaid Reforms: A Path to Recovery from Opioid Addiction
The percentage of caregivers prescribing buprenorphine increased faster after the Medicaid reforms implementation.
 Heavy Alcohol Drinking Put 1 In 3 Americans at Risk for Metabolic Syndrome
New study examined whether metabolic syndrome could be a reason for increased mortality from alcohol-associated liver disease (ALD) despite declining alcohol use.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

High Rates of Liver Disease Progression Seen in Non-alcoholic Fatty Liver Disease Patients Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests